Metsera, Inc. (MTSR)
| Market Cap | 3.11B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -265.84M |
| Shares Out | 105.06M |
| EPS (ttm) | -8.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,035,743 |
| Open | 29.50 |
| Previous Close | 27.71 |
| Day's Range | 28.33 - 30.67 |
| 52-Week Range | 12.30 - 37.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 55.25 (+86.66%) |
| Earnings Date | May 12, 2025 |
About MTSR
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. [Read more]
Analyst Forecast
According to 6 analysts, the average rating for MTSR stock is "Strong Buy." The 12-month stock price forecast is $55.25, which is an increase of 86.66% from the latest price.
News
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability wi...
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a mo...
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-...
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025
Metsera to Present at Bank of America 2025 Global Healthcare Conference
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesi...
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025
Metsera to Present at TD Cowen's 45th Annual Health Care Conference
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed signific...
Why this newly public biotech could become a force in obesity treatments
Metsera's GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.
This weight-loss drug stock could deliver a 90% return in 2025
Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31st. But analysts are convinced the recent price action is a drop in the bucket compared to where this s...
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company s...
Metsera Announces Pricing of Initial Public Offering
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. The firm's lead candidate, MET-097i, is in Phase 2b trials, w...
Weight-loss drug developer Metsera reveals wider loss in US IPO filing
Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S. initial public offering on Friday.
Metsera IPO Registration Document (S-1)
Metsera has filed to go public with an IPO on the NASDAQ.